Retrospective analysis of 235 unselected patients with mantle
cell lymphoma confirms prognostic relevance of Mantle Cell
Lymphoma International Prognostic Index and Ki-67 in the era of
rituximab: long-term data from the Czech Lymphoma Project
Database

J 2014

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database

ŠÁLEK, David, Pavla VESELÁ, Ludmila BOUDOVÁ, Andrea JANÍKOVÁ, Pavel KLENER et. al.

Basic information

Original name

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database

Authors

ŠÁLEK, David (203 Czech Republic, guarantor), Pavla VESELÁ (203 Czech Republic), Ludmila BOUDOVÁ (203 Czech Republic), Andrea JANÍKOVÁ (203 Czech Republic, belonging to the institution), Pavel KLENER (203 Czech Republic), Samuel VOKURKA (203 Czech Republic), Milada JANKOVSKA (203 Czech Republic), Robert PYTLIK (203 Czech Republic), David BELADA (203 Czech Republic), Jan PIRNOS (203 Czech Republic), Mojmír MOULIS (203 Czech Republic, belonging to the institution), Roman KODET (203 Czech Republic), Michal MICHAL (203 Czech Republic), Eva JANOUŠOVÁ (203 Czech Republic, belonging to the institution), Jan MUŽÍK (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Marek TRNĚNÝ (203 Czech Republic)

Edition

Leukemia & lymphoma, London, Informa Healthcare, 2014, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.891

RIV identification code

RIV/00216224:14110/14:00074886

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3109/10428194.2013.815349

UT WoS

000333582600013

Keywords in English

Mantle cell lymphoma; MIPI; Ki-67; proliferation; immunochemotherapy; prognosis

Abstract

V originále

Although a prognostic model (MIPI, Mantle Cell Lymphoma International Prognostic Index) for patients with mantle cell lymphoma (MCL) has been established, its clinical significance for daily practice in the rituximab era remains controversial. Data of 235 unselected patients with MCL from the Czech Lymphoma Project Database were analyzed. MIPI, simplified MIPI (s-MIPI) and Ki-67 proliferation index were assessed for all patients and for a subgroup of 155 rituximab-treated (RT) patients. MIPI divided all patients into subgroups of low-risk (22%), intermediate-risk (29%) and high-risk (49%), with median overall survival 105.8 vs. 54.1 vs. 24.6 months, respectively (p < 0.001). s-MIPI revealed similar results. The validity of both indexes was confirmed in RT patients. We confirmed the Ki-67 index to be a powerful single prognostic factor for overall survival (64.4 vs. 20.1 months, p < 0.001) for all patients and for the RT subset. Our results confirm the clinical relevance of MIPI, s-MIPI and Ki-67 for risk stratification in MCL also in the rituximab era.

Citovat

ŠÁLEK, David, Pavla VESELÁ, Ludmila BOUDOVÁ, Andrea JANÍKOVÁ, Pavel KLENER, Samuel VOKURKA, Milada JANKOVSKA, Robert PYTLIK, David BELADA, Jan PIRNOS, Mojmír MOULIS, Roman KODET, Michal MICHAL, Eva JANOUŠOVÁ, Jan MUŽÍK, Jiří MAYER and Marek TRNĚNÝ. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leukemia & lymphoma. London: Informa Healthcare, 2014, vol. 55, No 4, p. 802-810. ISSN 1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2013.815349.

@article{1139282,
   author = {Šálek, David and Veselá, Pavla and Boudová, Ludmila and Janíková, Andrea and Klener, Pavel and Vokurka, Samuel and Jankovska, Milada and Pytlik, Robert and Belada, David and Pirnos, Jan and Moulis, Mojmír and Kodet, Roman and Michal, Michal and Janoušová, Eva and Mužík, Jan and Mayer, Jiří and Trněný, Marek},
   article_location = {London},
   article_number = {4},
   doi = {http://dx.doi.org/10.3109/10428194.2013.815349},
   keywords = {Mantle cell lymphoma; MIPI; Ki-67; proliferation; immunochemotherapy; prognosis},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & lymphoma},
   title = {Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database},
   volume = {55},
   year = {2014}
}

TY  - JOUR
ID  - 1139282
AU  - Šálek, David - Veselá, Pavla - Boudová, Ludmila - Janíková, Andrea - Klener, Pavel - Vokurka, Samuel - Jankovska, Milada - Pytlik, Robert - Belada, David - Pirnos, Jan - Moulis, Mojmír - Kodet, Roman - Michal, Michal - Janoušová, Eva - Mužík, Jan - Mayer, Jiří - Trněný, Marek
PY  - 2014
TI  - Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database
JF  - Leukemia & lymphoma
VL  - 55
IS  - 4
SP  - 802-810
EP  - 802-810
PB  - Informa Healthcare
SN  - 10428194
KW  - Mantle cell lymphoma
KW  - MIPI
KW  - Ki-67
KW  - proliferation
KW  - immunochemotherapy
KW  - prognosis
N2  - Although a prognostic model (MIPI, Mantle Cell Lymphoma International Prognostic Index) for patients with mantle cell lymphoma (MCL) has been established, its clinical significance for daily practice in the rituximab era remains controversial. Data of 235 unselected patients with MCL from the Czech Lymphoma Project Database were analyzed. MIPI, simplified MIPI (s-MIPI) and Ki-67 proliferation index were assessed for all patients and for a subgroup of 155 rituximab-treated (RT) patients. MIPI divided all patients into subgroups of low-risk (22%), intermediate-risk (29%) and high-risk (49%), with median overall survival 105.8 vs. 54.1 vs. 24.6 months, respectively (p < 0.001). s-MIPI revealed similar results. The validity of both indexes was confirmed in RT patients. We confirmed the Ki-67 index to be a powerful single prognostic factor for overall survival (64.4 vs. 20.1 months, p < 0.001) for all patients and for the RT subset. Our results confirm the clinical relevance of MIPI, s-MIPI and Ki-67 for risk stratification in MCL also in the rituximab era.
ER  -

ŠÁLEK, David, Pavla VESELÁ, Ludmila BOUDOVÁ, Andrea JANÍKOVÁ, Pavel KLENER, Samuel VOKURKA, Milada JANKOVSKA, Robert PYTLIK, David BELADA, Jan PIRNOS, Mojmír MOULIS, Roman KODET, Michal MICHAL, Eva JANOUŠOVÁ, Jan MUŽÍK, Jiří MAYER and Marek TRNĚNÝ. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. \textit{Leukemia \&{} lymphoma}. London: Informa Healthcare, 2014, vol.~55, No~4, p.~802-810. ISSN~1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2013.815349.

Detailed Information on Publication Record